PDLLA3000-mPEG2000, PDI≤1.25 is an amphiphilic block copolymer composed of methoxy poly(ethylene glycol) and poly(D,L-lactide). PDLLA3000-mPEG2000, PDI≤1.25 functions as a self-assembled polymeric micelle component to enhance aqueous solubility and oral bioavailability in bioactive substances. PDLLA3000-mPEG2000, PDI≤1.25 can be used in the study of drug delivery [1] [2].
In Vivo, PDLLA3000-mPEG2000, PDI≤1.25 (2.5 mg/mL; i.g.; single dose), as part of Hyperoside-loaded polymeric micelles, increases the oral bioavailability of Hyperoside by 8-fold and extends its half-life by 3-fold in healthy male Sprague Dawley rats[1].
In Vitro, PDLLA3000-mPEG2000, PDI≤1.25, combined with d-α-tocopherol acid of polyethylene glycol succinat (TPGs), forms a homogeneous, stable spherical micellar system with a particle size of 67.42 nm, PDI of 0.229, and zeta potential of -18.67 mV when used to fabricate Hyperoside -loaded micelles via thin film dispersion[1]. PDLLA3000-mPEG2000, PDI≤1.25 (0.1-10 μg/mL; 12 h dark incubation), combined with TPGs, forms blank micelles with a critical micelle concentration of 2.56 μg/mL, indicating excellent self-assembly capability and stability[1]. PDLLA3000-mPEG2000, PDI≤1.25 (10-200 μg/mL; 48 h), combined with TPGs, forms blank micelles that exhibit low cytotoxicity[1]. PDLLA3000-mPEG2000, PDI≤1.25 forms stable spherical nanomicelles with glucose-Paclitaxel, achieving a high encapsulation efficiency of 95.59% and drug loading of 11.46%, with no significant changes in size or zeta potential over 28 days of storage at 25°C or 4°C[2].
References:
[1]. Xia X, et al. Hyperoside-loaded TPGs/mPEG-PDLLA self-assembled polymeric micelles: preparation, characterization and in vitro/in vivo evaluation. Pharm Dev Technol. 2022 Sep;27(7):829-841.
[2]. Yan D, et al. Nanomicellar Prodrug Delivery of Glucose-Paclitaxel: A Strategy to Mitigate Paclitaxel Toxicity. Int J Nanomedicine. 2025;20:2087-2101. Published 2025 Feb 17.
In Vivo, PDLLA3000-mPEG2000, PDI≤1.25 (2.5 mg/mL; i.g.; single dose), as part of Hyperoside-loaded polymeric micelles, increases the oral bioavailability of Hyperoside by 8-fold and extends its half-life by 3-fold in healthy male Sprague Dawley rats[1].
In Vitro, PDLLA3000-mPEG2000, PDI≤1.25, combined with d-α-tocopherol acid of polyethylene glycol succinat (TPGs), forms a homogeneous, stable spherical micellar system with a particle size of 67.42 nm, PDI of 0.229, and zeta potential of -18.67 mV when used to fabricate Hyperoside -loaded micelles via thin film dispersion[1]. PDLLA3000-mPEG2000, PDI≤1.25 (0.1-10 μg/mL; 12 h dark incubation), combined with TPGs, forms blank micelles with a critical micelle concentration of 2.56 μg/mL, indicating excellent self-assembly capability and stability[1]. PDLLA3000-mPEG2000, PDI≤1.25 (10-200 μg/mL; 48 h), combined with TPGs, forms blank micelles that exhibit low cytotoxicity[1]. PDLLA3000-mPEG2000, PDI≤1.25 forms stable spherical nanomicelles with glucose-Paclitaxel, achieving a high encapsulation efficiency of 95.59% and drug loading of 11.46%, with no significant changes in size or zeta potential over 28 days of storage at 25°C or 4°C[2].
References:
[1]. Xia X, et al. Hyperoside-loaded TPGs/mPEG-PDLLA self-assembled polymeric micelles: preparation, characterization and in vitro/in vivo evaluation. Pharm Dev Technol. 2022 Sep;27(7):829-841.
[2]. Yan D, et al. Nanomicellar Prodrug Delivery of Glucose-Paclitaxel: A Strategy to Mitigate Paclitaxel Toxicity. Int J Nanomedicine. 2025;20:2087-2101. Published 2025 Feb 17.